• T A Briscoe, D Anderson, O S Usifo, and G S Cooper.
• Department of Medicine, Morehouse School of Medicine, Atlanta, Georgia 30310, USA.
• J Natl Med Assoc. 1997 Nov 1; 89 (11): 728730728-30.

AbstractA retrospective analysis was conducted to determine the effects of metformin on glycosylated hemoglobin (HbA1c), body weight, and adverse events in an African-American population. Thirty-six patients who were receiving combination therapy with metformin and either a sulfonylurea or insulin were identified from a hospital pharmacy database. Nineteen patients met the criteria for efficacy analysis. The combination of metformin with either a sulfonylurea or insulin resulted in a decrease of the average HbA1c from a baseline of 10.07% to 7.92% (delta = 2.15%). The effect of combination therapy on weight was variable; however, twice as many patients lost weight compared with those who gained weight. Metformin appeared to be well-tolerated, with gastrointestinal symptoms being the most commonly reported adverse events.

35 keywords...

hide…